Jehovah’s Witnesses and blood transfusions: responding to the new guidance

  • Insight Article 2026年11月18日 2026年11月18日
  • 英国和欧洲

  • Regulatory movement

  • 保健

On 18 September 2026, new guidance from the Governing Body of Jehovah’s Witnesses marked a significant change in its longstanding approach to blood transfusions. For healthcare providers, this is an important development. The law on consent and capacity has not changed, but some of the assumptions historically made when treating Jehovah’s Witness patients will need to.

Until recently, Jehovah’s Witnesses were generally understood to refuse whole blood and its four primary components. Under the new guidance, individual Witnesses may now decide whether to accept red cells, white cells, plasma or platelets without risk of excommunication. The position on whole blood remains unchanged, however Jehovah’s Witness ban on accepting blood components in transfusions is lifted.

Consent and individual decision-making

A capacitous adult is entitled to consent to or refuse medical treatment, even where that decision may result in serious harm or death. Religious affiliation, however, should not be treated as a substitute for an individual treatment decision.

That distinction is now particularly important. A previous note that a patient is a Jehovah’s Witness, or even that they have previously refused “blood”, may not establish their current position on each individual blood component. Clinicians should therefore establish and clearly document which specific products a patient is willing to accept or refuse, rather than recording a blanket objection to “blood transfusion”. 

The BMJ similarly recommends establishing the individual patient's position and revisiting that discussion where circumstances change.

The established legal position

The Mental Capacity Act 2005 provides the framework for decision-making where an adult lacks capacity, while sections 24 to 26 govern advance decisions to refuse treatment. A valid and applicable advance decision refusing life-sustaining treatment must be respected.

The courts have long applied these principles in the context of Jehovah’s Witnesses. In HE v A Hospital NHS Trust [2003] EWHC 1017 (Fam), the High Court confirmed that a valid advance refusal of blood transfusion could remain binding after the patient subsequently lost capacity. More recently, in PW (Jehovah’s Witness: Validity of Advance Decision) [2021] EWCOP 52, the Court of Protection concluded that an advance decision refusing blood products was valid and applicable and had to be respected, notwithstanding that the proposed treatment was considered necessary to save PW’s life.

What has changed is therefore not the law, but the factual context in which it operates. Following the new guidance, clinicians should be cautious about treating a patient's faith, or an historic reference to refusing “blood”, as determinative of what that individual would accept today.

What if the patient cannot decide?

The position becomes more difficult where a Jehovah’s Witness patient presents unconscious or otherwise lacks capacity.

Clinicians will need to consider whether there is a valid and applicable advance decision, whether a health and welfare attorney has relevant authority, and what other reliable evidence exists of the patient's wishes and beliefs.

Historic documentation may now require particularly careful consideration. An older record stating simply that the patient refuses “blood” may not answer whether they would accept particular blood components under the new guidance. Equally, the change in guidance does not of itself invalidate a properly made advance decision. The individual document, its wording, validity and applicability to the treatment proposed will remain critical.

Where there is genuine uncertainty or disagreement about capacity, an advance decision or the patient's best interests, early legal advice may be required and, in serious cases, an application to the Court of Protection may be necessary.

What should healthcare providers do?

The change provides a timely opportunity for NHS Trusts and other healthcare providers to review their approach. Organisations should consider:

  • updating policies and clinical guidance concerning Jehovah’s Witness patients;
  • ensuring records distinguish between whole blood and individual blood components;
  • reminding clinicians not to assume what treatment a patient will accept based on their faith;
  • clearly documenting discussions about individual blood products; and
  • seeking legal advice early where capacity, advance decisions or serious medical treatment are in issue.

Conclusion

For healthcare providers, the principal risk is assumption. An outdated understanding of a patient's beliefs could result in treatment being withheld which they would in fact have accepted. Conversely, the new guidance should not be taken to mean that Jehovah’s Witness patients will now accept blood components.

The safest approach remains the most legally familiar: ask, document and, where capacity or serious medical treatment issues arise, act early.

结束

主题:

Clyde.Insights.Areas:

  • Legal Development

掌握其礼的最新消息

注册您的邮箱,获取其礼最新消息!